PRESS RELEASE published on 06/13/2025 at 01:25, 10 months 22 days ago Moderna Receives U.S. FDA Approval for RSV Vaccine, mRESVIA, in Adults Aged 18–59 at Increased Risk for RSV Disease Moderna receives FDA approval to expand indication of mRESVIA vaccine for adults aged 18-59 at increased risk of RSV, based on Phase 3 study results showing safety and efficacy FDA Approval Moderna RSV Vaccine Phase 3 Study MRESVIA
BRIEF published on 06/11/2025 at 13:05, 10 months 24 days ago Moderna to Present at Barclays Science Call Series MRNA Technology Presentation Moderna Barclays Investor Event
BRIEF published on 06/11/2025 at 13:05, 10 months 24 days ago Moderna participera à la série d'appels scientifiques de Barclays Presentation Barclays Moderne Événement Pour Les Investisseurs Technologie De L'ARNm
PRESS RELEASE published on 06/11/2025 at 13:00, 10 months 24 days ago Moderna to Present at Upcoming Barclays Speaking the Science Call Series on June 16, 2025 Moderna, Inc. announces participation in Barclays Speaking the Science Call Series on June 16th at 10:00am ET. Webcast available on Moderna's website Webcast MRNA Medicine Moderna Barclays Investor Event
BRIEF published on 05/31/2025 at 06:21, 11 months 5 days ago Moderna's mNEXSPIKE COVID-19 Vaccine Secures FDA Approval FDA Approval COVID-19 Vaccine Clinical Trial Moderna MNEXSPIKE
BRIEF published on 05/31/2025 at 06:21, 11 months 5 days ago Le vaccin mNEXSPIKE de Moderna contre la COVID-19 obtient l'approbation de la FDA Essai Clinique Approbation De La FDA Moderne Vaccin Contre Le Covid-19 MNEXSPIKE
PRESS RELEASE published on 05/31/2025 at 06:16, 11 months 5 days ago Moderna Receives U.S. FDA Approval for COVID-19 Vaccine mNEXSPIKE Moderna's mNEXSPIKE, a new COVID-19 vaccine, receives FDA approval for high-risk age groups. The vaccine shows higher efficacy compared to the original mRNA-1273. Safety profile similar to Spikevax FDA Approval COVID-19 Vaccine Moderna Efficacy MNEXSPIKE
BRIEF published on 05/29/2025 at 00:05, 11 months 7 days ago Moderna Reports Progress and Setback in Avian Flu Vaccine Program Moderna Vaccine Development Phase 1/2 Study H5 Avian Flu MRNA-1018
BRIEF published on 05/29/2025 at 00:05, 11 months 7 days ago Moderna fait état de progrès et de revers dans son programme de vaccination contre la grippe aviaire Développement De Vaccins Moderne Étude De Phase 1/2 Grippe Aviaire H5 ARNm-1018
PRESS RELEASE published on 05/29/2025 at 00:00, 11 months 7 days ago Moderna Announces Update on Investigational Pandemic Influenza Program Moderna's Phase 1/2 H5 avian flu vaccine study shows positive interim results with robust immune response. HHS terminates late-stage development award Moderna Phase 1/2 Study Avian Flu Vaccine H5 Subtype HHS Termination
Published on 05/05/2026 at 13:20, 15 minutes ago Gold Basin Resources Refutes Helix Resources April 29, 2026 ASX Annoucement
Published on 05/05/2026 at 13:05, 30 minutes ago CoTec Holdings Corp. Upgrades to OTCQX(R) Best Market
Published on 05/05/2026 at 13:00, 35 minutes ago Atha Energy Completes Mobilization & Commences Diamond Drilling Operations as Part of the 2026 Angilak Exploration Program – Fully Funded and Largest to Date at the Project
Published on 05/05/2026 at 13:00, 35 minutes ago NOA Engages Hatch To Lead Process Development Study To Support Upcoming PFS At Rio Grande Project
Published on 05/05/2026 at 13:00, 35 minutes ago Eagle Plains Adds Additional Dispositions at the Pine Channel Au Project, Northern Saskatchewan
Published on 05/05/2026 at 13:06, 29 minutes ago Commerzbank Takes Note of Publication of UniCredit’s Offer Document
Published on 05/05/2026 at 13:02, 32 minutes ago Commerzbank Takes Note of Publication of UniCredit’s Offer Document
Published on 05/05/2026 at 12:30, 1 hour 5 minutes ago FUCHS honored with “John Deere Supplier of the Year Award 2025”
Published on 05/05/2026 at 12:17, 1 hour 17 minutes ago EQS-Adhoc: hep global GmbH: Bondholders of the Green Bond 2021/2026 approve an extension of the term of the Green Bond 2021/2026 under modified conditions
Published on 05/05/2026 at 11:15, 2 hours 19 minutes ago Informations relatives au nombre total de droits de vote et d’actions
Published on 05/05/2026 at 08:00, 5 hours 35 minutes ago KLARSEN : Ouverture d’une procédure de redressement judiciaire auprès du Tribunal judiciaire de Strasbourg pour la filiale ITL
Published on 05/05/2026 at 07:57, 5 hours 38 minutes ago Signing of an agreement to acquire the Scholz Recycling Group
Published on 05/05/2026 at 07:57, 5 hours 38 minutes ago Signature d’un contrat en vue de l’acquisition du groupe Scholz Recycling
Published on 05/04/2026 at 20:57, 16 hours 38 minutes ago Covivio - Information on total number of voting rights and share capital
